Medicare Part D coverage · roflumilast · RxCUI 2671684
roflumilast 3 MG/ML Topical Foam [Zoryve]
Per the CMS 2026 Part D formulary file, roflumilast 3 MG/ML Topical Foam [Zoryve] is covered by 818 Medicare Part D plans (16.2% of enrollable products), averaging Tier 3.7, with prior authorization required on 100% of covering formularies.
- 16.2%
- Plan coverage
- 818
- Plans covering
- T3.7
- Avg tier
- 100%
- Prior auth required
What the CMS Formulary Data Shows for roflumilast 3 MG/ML Topical Foam [Zoryve]
Per the CMS 2026 Part D formulary file, roflumilast 3 MG/ML Topical Foam [Zoryve] (RxNorm concept RXCUI 2671684, generic name roflumilast) appears on 7 distinct formulary files spanning 818 Medicare Part D plan offerings - 16.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 4, with a cross-plan average of Tier 3.7.
Real-world access to roflumilast 3 MG/ML Topical Foam [Zoryve] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 14.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 59,491 Part D beneficiaries filled roflumilast 3 MG/ML Topical Foam [Zoryve] in 2023, with total plan-and-beneficiary spending of $60,127,502 and an average per-beneficiary annual cost of $1,010.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry roflumilast 3 MG/ML Topical Foam [Zoryve] today.
Coverage Details
- Formularies covering
- 7
- Plans covering
- 818
- Coverage rate
- 16.2%
- Tier range
- Tier 2 – Tier 4
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 14.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 59,491
- Total spending
- $60,127,502
- Avg per beneficiary
- $1,010.70
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering roflumilast 3 MG/ML Topical Foam [Zoryve]
5 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Saver from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Saver from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T4 | Yes | No | $0 | - |
| AARP Medicare Rx Saver from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T4 | Yes | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering roflumilast 3 MG/ML Topical Foam [Zoryve]
95 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CalOptima Health OneCare Complete (HMO D-SNP) | Orange County Health Authority | T2 | Yes | $0 | CA |
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T4 | Yes | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T4 | Yes | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T4 | Yes | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T4 | Yes | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T4 | Yes | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T4 | Yes | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T4 | Yes | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T4 | Yes | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T4 | Yes | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T4 | Yes | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T4 | Yes | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T4 | Yes | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T4 | Yes | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T4 | Yes | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T4 | Yes | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T4 | Yes | $0 | VA |
| AARP Medicare Advantage from UHC AL-0001 (HMO-POS) | Unitedhealthcare OF THE Midlands, Inc. | T4 | Yes | $0 | AL |
| AARP Medicare Advantage from UHC CA-0002 (HMO-POS) | UHC OF California | T4 | Yes | $0 | CA |
| UHC Sharp Medicare Advantage CA-001P (HMO-POS) | UHC OF California | T4 | Yes | $0 | CA |
Show the next 30 plans
Showing top 50 of 95 plans.
Frequently Asked Questions
Is roflumilast 3 MG/ML Topical Foam [Zoryve] covered by Medicare Part D?
Yes, roflumilast 3 MG/ML Topical Foam [Zoryve] is covered by 818 Medicare Part D plans (16.2% of all Part D formularies).
What tier is roflumilast 3 MG/ML Topical Foam [Zoryve] on Medicare Part D plans?
roflumilast 3 MG/ML Topical Foam [Zoryve] averages Tier 3.7 across Part D plans, ranging from Tier 2 to Tier 4.
Does roflumilast 3 MG/ML Topical Foam [Zoryve] require prior authorization?
100% of Part D formularies require prior authorization for roflumilast 3 MG/ML Topical Foam [Zoryve]. Step therapy: 0%. Quantity limits: 14.3%.
How much does Medicare spend on roflumilast 3 MG/ML Topical Foam [Zoryve]?
In 2023, total Medicare Part D spending on roflumilast 3 MG/ML Topical Foam [Zoryve] was $60,127,502, covering 59,491 beneficiaries. The average spend per beneficiary was $1,010.70.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- zonisamide 20 MG/ML Oral Suspension [Zonisade] T3.7
- lisdexamfetamine dimesylate 40 MG Chewable Tablet T3.7
- mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] T3.7
- tacrolimus 5 MG Oral Capsule [Prograf] T3.7
- droxidopa 200 MG Oral Capsule T3.7
- lactulose 10000 MG Powder for Oral Solution [Kristalose] T3.7
Similar prior-authorization rate
- azathioprine 50 MG Oral Tablet 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B] 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- 1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- sotagliflozin 200 MG Oral Tablet [Inpefa] 100% PA
- mycophenolate mofetil 250 MG Oral Capsule 100% PA